Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases

CS Santos, SC Antolin, CM Morales, JG Herrero… - RMD open, 2022 - rmdopen.bmj.com
Background Patients with immune-mediated rheumatic diseases (IMRDs) are commonly
treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS …

Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for …

A Mosquera Orgueira… - British Journal of …, 2024 - Wiley Online Library
Chronic myelomonocytic leukaemia (CMML) is a rare haematological disorder characterized
by monocytosis and dysplastic changes in myeloid cell lineages. Accurate risk stratification …

Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry …

I Navarro Vicente, P Lloret Madrid, A Solana-Altabella… - Blood, 2023 - ashpublications.org
Background BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm) is a rare and
aggressive hematological neoplasm, and due to its rarity there are scarce registry studies …

Inherited Thrombocytopenias Predisposing to Hematologic Neoplasms. Experience of the Spanish Group for Inherited Platelet Disorders (GEAPC)

JM Bastida, A Marín-Quílez, A Zamora… - Blood, 2023 - ashpublications.org
Objective The aim of this study was to evaluate the frequency, clinical characteristics,
platelet phenotype and molecular alterations of patients with IT predisposing to HM, within …

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged≥ 60 Years Old with FLT3 Mutated Acute Myeloid …

GA Requena, PY Dumas, RR Veiga, S Bertoli, C Gil… - Blood, 2023 - Elsevier
BACKGROUND: The prognosis of patients with acute myeloid leukemia (AML) varies
depending on the presence of mutations in the FLT3 tyrosine kinase. Internal tandem …

[HTML][HTML] P703: THE AIPSS-MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF …

A Mosquera-Orgueira, MMP Encinas, ND Varela… - …, 2023 - journals.lww.com
Background: Chronic myelomonocytic leukemia (CMML) is a type of hematological stem cell
disorder characterized by dysplasia, myeloid proliferation, cytopenias and increased risk of …

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic …

D Martinez-Cuadron, B Boluda, JL Algarra… - Blood, 2023 - Elsevier
Background: Current treatment of unfit acute myeloid leukemia (AML) patients include
hypomethylating agents (HMA) with or without venetoclax, low-dose cytarabine (LDAC), and …

Management of Massive Splenomegaly: A case report of a patient with a hematological malignancy

JHH Kok, TG Santos, HC García, FR Ortega… - European Journal of …, 2022 - ejso.com
Background: Massive splenomegaly lacks a consensus definition. It can be a spleen of more
than 1 kg in mass or more than 22cm in length. Splenectomy is indicated for several …

Wilms' Tumor 1 Expression Levels in Bone Marrow after Induction and/or Consolidation Therapy Allow a Better Stratification of Patients and Improves Treatment in …

C Martínez-Laperche, M Kwon, AC Franco, C Chillon… - 2014 - ashpublications.org
Abstract Introduction: The Wilms' tumor 1 (WT1) gene, located on chromosome 11p13,
encodes a transcription factor. WT1 is overexpressed in 90% of patients with acute myeloid …

Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for …

AM Orgueira, MMP Encinas, ND Varela… - British journal of … - pubmed.ncbi.nlm.nih.gov
Chronic myelomonocytic leukaemia (CMML) is a rare haematological disorder characterized
by monocytosis and dysplastic changes in myeloid cell lineages. Accurate risk stratification …